Results 81 to 90 of about 644,370 (183)

Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells

Breast Cancer Research, 2017
Background Approximately 70% of all breast cancers express the estrogen receptor, and are regulated by estrogen. While the ovaries are the primary source of estrogen in premenopausal women, most breast cancer is diagnosed following menopause, when ...
Derek F. Amanatullah, John S. Tamaresis, Pauline Chu, Michael H. Bachmann, Nhat M. Hoang, Deborah Collyar, Aaron T. Mayer, Robert B. West, William J. Maloney, Christopher H. Contag, Bonnie L. King   +10 more
doaj   +1 more source

Synthesis and Characterization of Azole Isoflavone Inhibitors of Aromatase [PDF]

, 2005
The synthesis and biological evaluation of a series of 2-azole and 2-thioazole isoflavones as potential aromatase inhibitors are described. Differences in inhibitory activity of triazole and imidazole inhibitors are rationalized with density functional ...
Kim, Young Woo, Hackett, John C., Su, Bin, Brueggemeier, Robert W.   +3 more
core   +1 more source

Do aromatase inhibitors have adverse effects on cognitive function?

, 2011
Aromatase inhibitors are an important component of treatment for most postmenopausal women with hormone receptor-positive, early-stage breast cancer. Women taking aromatase inhibitors experience very low levels of circulating estrogen.
Fisher, R, Ribi, K, Phillips, KA
core   +1 more source

Association study of aromatase inhibitors and adverse events related to osteoporosis: based on pharmacovigilance data. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Yang N, Zhang W, Cui X, Xi L, Zhou Y, Feng H.   +5 more
europepmc   +1 more source

Differential Effectiveness of Aromatase Inhibitors in Hormone Receptor-Positive Breast Cancer. [PDF]

JAMA Netw Open
Pinheiro LC, Rosenberg SM.
europepmc   +1 more source

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases. [PDF]

Front Med (Lausanne)
Fan Z, Sun P, Li L.
europepmc   +1 more source

<i>FADS</i> genotypes shape plasma polyunsaturated fatty acids independently of dietary intake in breast cancer survivors on aromatase inhibitors. [PDF]

Front Nutr
Pokimica B, Vucic V, Petrovic S, Bobic S, Djurisic I, Petrovic A, Milosevic M.   +6 more
europepmc   +1 more source

Longitudinal monitoring of denosumab-associated bone changes by REMS in postmenopausal women with ER-positive breast cancer receiving aromatase inhibitors. [PDF]

Aging Clin Exp Res
Caffarelli C, Forcignanò R, Muratore M, Gonnelli S.   +3 more
europepmc   +1 more source

Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors. [PDF]

Cancers (Basel)
Popescu R, Flangea C, Vlad DC, Cobec IM, Seropian P, Marina CD, Vlad T, Dumitrascu AL, Puscasiu D.   +8 more
europepmc   +1 more source

Aromatase inhibitors induce pain-like musculoskeletal symptoms in mice: behavioural, pharmacological and pathophysiological characterization. [PDF]

Br J Pharmacol
Caillaud M, Herz SM, Koseli E, Roberts J, Ulker E, Jessup D, McKiver B, Silva GM, Betancourt-Toscano I, Diaz NJ, Khan A, Poklis JL, Henry NL, Akbarali H, Damaj MI.   +14 more
europepmc   +1 more source